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The detection of microbial DNA but not cultured bacteria is associated with increased mortality in patients 1 
with suspected sepsis – a prospective multi-centre European observational study 2 
Microbial DNA increases mortality in patients with sepsis 3 
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Abstract 29 
Objectives  30 
Blood culture results inadequately stratify the mortality risk in critically ill patients with sepsis. We sought to 31 
establish the prognostic significance of the presence of microbial DNA in the bloodstream of patients hospitalised 32 
with suspected sepsis. 33 
Methods  34 
We analysed the data collected during the Rapid Diagnosis of Infections in the Critically Ill (RADICAL) study 35 
which compared a novel culture-independent polymerase chain reaction/electrospray ionization-mass spectrometry 36 
(PCR/ESI-MS) assay with standard microbiological testing. Patients were eligible for the study if they were having 37 
suspected sepsis and were either hospitalised or were referred to one of nine intensive care units from six European 38 
countries. Blood specimen for PCR/ESI-MS assay was taken along with initial blood culture taken for clinical 39 
indications. 40 
Results 41 
Of the 616 patients recruited to the RADICAL study, 439 patients had data on outcome, results of the blood culture 42 
and PCR/ESI-MS assay available for analysis. Positive blood culture and PCR/ESI-MSI result was found in 13% 43 
(56/439) and 40% (177/439) of patients respectively. Either a positive blood culture (p=0.01) or a positive PCR/ESI-44 
MS (p=0.005) was associated with higher SOFA scores on enrolment to the study. There was no difference in 28 45 
days mortality observed in patients who had either positive or negative blood cultures (35% versus 32%, p=0.74). 46 
However, in patients with a positive PCR/ESI-MS assay mortality was significantly higher in comparison to those 47 
with a negative result (42% versus 26%, p=0.001). 48 
Conclusions  49 
Presence of microbial DNA in patients with suspected sepsis might define a patient group at higher risk of death.  50 
 51 
Key words: culture-independent; molecular detection; early-diagnosis; critically ill; infection; mortality 52 
 53 
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Introduction 57 
Sepsis is one of the major causes of worldwide mortality [1]. Within the intensive care unit (ICU) sepsis comprises 58 
one quarter of admissions yet accounts for almost half of all bed days [2]. Although decreasing, the mortality rate 59 
associated with sepsis remains far in excess of that observed for other ICU admission diagnoses [3,4]. Early 60 
identification and immediate treatment with appropriate antibiotic therapy is a central component of effective care of 61 
the septic patient [5-7]. However, traditional culture-based pathogen detection and identification methods are 62 
inherently slow, with up to 72 hours required to generate a complete result and fail to identify an organism in up to 63 
40% of cases with severe sepsis [8]. Furthermore, even when organisms are detected by culture techniques in cases 64 
of suspected sepsis this approach fails to consistently identify a patient group with an increased mortality risk [9-11].  65 
Our group has recently described the clinical performance of a novel technology involving polymerase chain 66 
reaction that is followed by electrospray ionization mass spectrometry (PCR/ESI-MS) in a multicentre observational 67 
study of patients with suspected sepsis referred to the ICU for further management (The RADICAL study) [12]. 68 
This technology is non-culture based and can detect the DNA of in excess of 800 relevant pathogens within 69 
approximately six hours. In the previous paper we reported that PCR/ESI-MS identified a relevant pathogen in the 70 
blood stream nearly four times more frequently than blood cultures in addition to having a 97% negative predictive 71 
value.   72 
Data from the RADICAL study may offer important new information regarding the clinical significance of the 73 
detection of microbial DNA in the blood stream of patients referred for ICU treatment with a suspected infection. 74 
Here we describe an analysis of those patients recruited to the RADICAL study where matching data were available 75 
describing patient outcome, blood culture and PCR/ESI-MS findings. Our hypothesis was that the presence of 76 
microbial DNA in the bloodstream of patients with suspected sepsis may more effectively identify a cohort of 77 
patients at higher risk of death from sepsis, regardless of whether viable microbes were isolated from blood culture. 78 
 79 
 80 
 81 
 82 
 83 
 84 
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Methods  85 
In this study we analysed the data from the observational multi-centre study Rapid Diagnosis of Infections in the 86 
Critically Ill (RADICAL). Detailed trial methods of the RADICAL study and results of the primary analysis were 87 
published previously [12]. The RADICAL study was conducted in nine intensive care units (ICUs) from six 88 
European countries. Written informed consent was sought and recorded from each participant or their legal 89 
representative. Research ethics approval was obtained in each participating centre and therefore the study has been 90 
conducted in accordance with the ethical standards of the Declaration of Helsinki and its following amendments.  91 
The analysis presented describes those patients recruited to RADICAL where study blood specimens were obtained 92 
simultaneously for both standard blood culture analysis and PCR/ES-MS analysis and outcome data for the patients 93 
were available.  94 
 95 
Patients 96 
Patients were enrolled to the RADICAL study between October 2013 and Jun 2014. Adult patients (≥18 yrs) were 97 
eligible for the study should they either 1. have a suspected or proven severe infection or sepsis and were either 98 
hospitalised or were referred for treatment to the ICU, or 2. had suspected or proven clinical diagnosis of 99 
pneumonia. To be eligible for enrolment into pneumonia group patients had to be intubated with an endotracheal 100 
tube and have proven or suspected clinical diagnosis of either severe community-acquired pneumonia (sCAP), 101 
healthcare-associated pneumonia (HAP/HCAP) or ventilator-associated pneumonia (VAP) defined by the presence 102 
of the following criteria: new infiltrates on chest radiograph plus temperature >38oC or <35oC, or increased 103 
production of sputum, or abnormal white blood cell count (>12 or <4 cells/mL3). Alternatively, pneumonia could be 104 
diagnosed if the treating clinician was clinically suspecting pneumonia and was expecting the patient to remain 105 
intubated the next day. Exclusion criteria were: palliative intention of the treatment, death was deemed imminent or 106 
inevitable, the treating clinician was not committed to aggressive therapy or was predicting discharge of the patient 107 
from the ICU on the day of evaluation, or the next day, or the patient has been readmitted to ICU during same 108 
hospitalization. 109 
 110 
Collection and processing of the specimen 111 
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Blood specimens were collected when treating physicians requested blood cultures due to clinical suspicion of a 112 
blood stream infection, pneumonia or an infection at a sterile site. Standard-of-care microbiology cultures were run 113 
according to local policy in every institution. For PCR/ESI-MS assay, a sample of minimum 5 mL of whole blood 114 
was taken from the same venepuncture as for blood culture testing into an Ethylene Diamine Tetra Acetic acid 115 
(EDTA) tube. All samples were cooled to 4°C within 30 min from obtaining and stored at 4°C or frozen at -20°C 116 
until further analysis. The technique of extraction of the genomic deoxyribonucleic acid (gDNA) from previously 117 
collected blood specimens was published previously [12]. Eluates from the extraction were transferred into 16 wells 118 
(30 µl per well) of a custom-mase PCR assay strip prefilled (25 µl per well) with 18 unique primer pairs and 119 
concentrated PCR master mix. Details of the primer sequences, gene targets, and configuration have been published 120 
elsewhere [12]. General PCR formulas and thermocycling conditions also have been published previously [12]. 121 
Potential contaminants were excluded from the analysis [12]. 122 
Blood culture results were available to treating clinicians according to the standard local protocols and the study 123 
team did not influence the treatment delivered to the patient by the treating clinicians. The treating clinicians 124 
remained unaware of the results of the PCR/ESI-MS assay.  125 
 126 
Clinical data collection 127 
Clinical and demographic data were obtained on study enrolment. Patients were followed up for 28 days. Sequential 128 
Organ Failure Assessment (SOFA) score was noted at enrolment to the study [13]. A quick SOFA (qSOFA) score 129 
was obtained retrospectively based on the data available in the original dataset [14]. Vasopressors were defined as 130 
either noradrenaline or vasopressin. Vital status at 28 days was recorded. Foci of infection were recorded as the 131 
suspicion of the treating clinicians. 132 
 133 
Statistical analysis 134 
Discrete variables are expressed as counts with percentages in parenthesis. Continuous variables were assessed for 135 
normality of distribution using the Shapiro-Wilk W test. Continuous variables that were non-normally distributed 136 
were described as median with interquartile range. All statistical tests are two-sided and a p-value of p<0.05 was 137 
considered significant. Differences in discrete variables were calculated with a chi-squared test and differences in 138 
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continuous variables assessed with a Wilcoxon Rank Sum Test. A McNemar test was used to compare paired 139 
categorical data. 140 
A binary multiple logistical regression model was run where 28 day mortality was the dependent variable. All 141 
plausible demographic and clinical data were first assessed for an association with 28 day mortality in a series of 142 
univariable analyses. Variables with a p value <0.2 with 28 day mortality were then added to the multiple logistical 143 
regression model as independent variables. The model was developed with backward selection. The majority of 144 
variables, including our variables of interest, were dichotomous therefore precluding the need to test for linearity. 145 
We did not hypothesise any particular interactions in our model building process and our sample size was 146 
insufficient to test for multiple interactions. Model building is described more systematically in the legend of 147 
supplemental table 1. Data analysis was performed using the JMP (version 10) statistical software (SAS, Cary, NC, 148 
USA). 149 
 150 
 151 
 152 
 153 
 154 
 155 
 156 
 157 
 158 
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 167 
 168 
Results 169 
Of the 616 patients recruited to the primary study [12], temporally matching results of the blood culture and 170 
PCR/ESI –MS assay were available for 439 patients and matching assays and 28 day mortality data was available 171 
for 365 patients. Table 1 describes the patient demographics and their clinical characteristics. Positive blood culture 172 
and PCR/ESI-MSI result was found in 13% (56/439) and 40% (177/439) of patients respectively. Concordance 173 
between blood cultures and PCR/ESI-MS assay has been described elsewhere [12]. Patients with positive PCR/ESI-174 
MS results were slightly older in comparison to those with a negative result (p=0.01, Table 1). Patients with either a 175 
positive blood culture or PCR / ESI-MS were more likely to have higher SOFA scores (p=0.01 and p=0.005, 176 
respectively) and require vasopressors (p=0.04 and p=0.02, respectively) on study enrolment but were less likely to 177 
have a pre-existing diagnosis of respiratory disease (p=0.03 and 0.04, respectively) than patients with negative test 178 
results (Table 1).  179 
 180 
Critical Illness characteristics 181 
The median length of stay in the ICU was 7 (4-14) days. Patients with positive PCR/ESI-MS result were ventilated 182 
for one extra day and remained shocked for two additional days (Table 2). The median number of days with 183 
antibiotic treatment was 7 (4-11) days and was not associated with the test result (Table 2). In patients with positive 184 
PCR/ESI-MS test result, the duration of antibiotics in patients whose blood culture result was positive was 6 (3-13) 185 
days compared to 8 days (4-13) (p=0.05) when the blood culture result was negative. In those patients that had a 186 
negative blood culture result, the duration of antibiotic therapy was similar between the patients with positive and 187 
negative PCR/ESI-MS results, respectively 8 (4-13) versus 7 (3-11), p=0.2.  188 
Patients with negative PCR/ESI-MS result had a greater number of days alive and free of antibiotics than patients 189 
with a positive result (Table 2). In patients whose PCR/ESI-MS test result was positive the number of days alive and 190 
free of antibiotics to day 28 was not dependent on the blood culture result (3 days (0-21) versus 4 days (0-22), 191 
p=0.7). Those patients with negative blood culture results who also had a negative PCR/ESI-MS result had greater 192 
numbers of days alive and free of antibiotics to day 28 than those who had a negative blood culture and a positive 193 
PCR/ESI-MS result (17 days (1-23) versus 3 days (0-21), p=0.005). 194 
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   195 
Outcomes 196 
Mortality rate at 28-day was 32% (118/365). Positive blood culture result was not associated with higher 28-day 197 
mortality (17/49 (35%) versus 101/316 (32%), p=0.7 for positive and negative blood cultures respectively). 198 
Conversely, 28-day mortality was significantly higher in patients with positive PCR/ESI-MS assay in comparison to 199 
those with negative PCR/ESI-MS result (62/147 (42%) versus 56/218 (26%), p=0.001 respectively). The odds ratio 200 
for 28-day mortality when the microbial DNA was detected by PCR/ESI-MS assay was 2.1 (95% CI 1.4-3.3).  201 
In patients with negative blood culture results, a positive PCR/ESI-MS test result remained strongly associated with 202 
increased rates of death (45/103 (44%) vs. 56/213 (26%), p=0.003, odds ratio for 28-day mortality 2.2 (1.3-3.6), 203 
Figure 1). In keeping with the high negative predictive value of PCR/ESI-MS, only five patients (1.4%) had positive 204 
blood cultures despite a negative PCR/ESI-MS, all these patients survived, however due to small sample size 205 
statistical significant versus rates of death with positive blood cultures and positive PCR/ESI-MS was not achieved 206 
(p=0.15). 207 
Univariable analyses demonstrated that increasing patient age (p<0.0001), a history of cancer (p=0.02), the presence 208 
of immune suppression (p=0.04) and a higher SOFA score on admission (p<0.0001) were associated with an higher 209 
risk of death at 28 days. None of: cardiovascular disease, respiratory disease, diabetes, chronic kidney disease, 210 
cirrhosis or smoking history were associated with 28-day mortality. In a multivariable logistical regression model, 211 
when the significant covariates were added to the model the presence of a positive PCR/ESI-MS result remained 212 
independently associated with 28-day mortality (Table 3 and supplemental table 1). When the blood culture result 213 
was also added to the model this was not independently associated with outcome but addition of the blood culture 214 
result as a covariate further strengthened the association between the PCR/ESI-MS result and 28 day mortality. 215 
 216 
Organism specific outcomes 217 
A full description of the organisms identified by both blood culture and PCR/ESI-MS techniques has been reported 218 
elsewhere [12]. In the cohort analysed for this study 35 patients had a Gram negative bacteria and 18 patients had a 219 
Gram positive bacteria isolated by blood culture. The 28 day mortality rate for the five most commonly isolated 220 
organisms by blood culture was: Escherichia coli 60% (6/15), Staphylococcus aureus 11% (1/9), Klebsiella 221 
pneumoniae 75% (3/4), Pseudomonas aeruginosa 50% (2/4), Enterococcus faecium 50% (1/2). 222 
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The 28 day mortality rate for the five most commonly isolated organisms by PCR / ESI-MS was: E. coli 43% 223 
(23/53), S. aureus 40% (8/20), E. faecium 11/17 (65%), K. pneumoniae 40% (4/10), and Candida albicans 56% 224 
(5/9). 225 
There were four cases of methicillin-resistant Staphylococcus aureus in blood cultures and seven cases detected with 226 
PCR/ESI-MS. The four cases were concordant between the two groups. There was one case of vancomycin-resistant 227 
enterococci which was matched between blood culture and PCR/ESI-MS. No case of carbapenemase-producing 228 
organism was detected by either methodology. 229 
There was no statistically significant difference between the mortality rates attributed to infection by any of the 230 
organisms, by whether the infection was Gram positive, Gram negative or fungal or by the presence of resistant 231 
organisms. 232 
The most commonly identified source of infection was the respiratory tract in 157 (36%) cases. Intra-abdominal 233 
infection accounted for 81 (18%) cases, primary blood stream infections for 70 (16%) cases, urinary tract infection 234 
for 32 (7%) cases and the source was unknown in 27 (6%) of cases. There was no relation between the source of 235 
infection and 28-day mortality was identified.  236 
 237 
 238 
 239 
 240 
 241 
 242 
 243 
 244 
 245 
 246 
 247 
 248 
 249 
 250 
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Discussion 251 
The principal finding of this analysis is that mortality was greater amongst patients referred to an ICU team for 252 
treatment of suspected sepsis when microbial DNA was detected with the PCR/ESI-MS assay.  In contrast to this 253 
finding, we found no difference in mortality rate between those patients with positive and negative blood culture. 254 
These findings might suggest that, apart from providing a more immediate microbiological diagnosis, PCR/ESI-MS 255 
may more effectively identify critically ill patients with active infection and hence an increased risk of death. We 256 
suggest that these data are consistent with a biologically important mechanism and describe a qualitatively different 257 
patient population with evidence of active infection that is missed using current microbiological diagnostics.  258 
The patients analysed were typical of an ICU population with sepsis. Patients were predominantly male and a 259 
median age of 65 years and frequently possessed significant co-morbidities. On presentation, the septic illness was 260 
severe.  The median SOFA score was seven and more than 50% of the patients were requiring immediate 261 
cardiovascular support and mechanical ventilation. More than half of the patients studied received a dose of 262 
antibiotic prior to study enrolment which likely reflects current guidelines recommending intravenous antibiotic 263 
treatment within the first hour following diagnosis of severe acute infection [7]. Prior antibiotic exposure is a key 264 
factor in the high incidence of culture-negative suspected sepsis and is also likely to interfere with the discriminant 265 
ability of blood culture in relation to patient outcome [15]. Consequently, blood culture does not consistently 266 
distinguish between non-survivors and survivors in patients with sepsis [8-11]. 267 
It is difficult to draw firm conclusions as to why patients with detectable microbial DNA in the PCR/ESI-MS assay 268 
had higher mortality rate. Although older, sicker patients were more likely to both have a positive PCR/ESI-MS 269 
assay and to subsequently die, the relationship between PCR/ESI-MS result and mortality remained following 270 
correction for these covariates. The key question that arises is whether the detection of microbial DNA is indicative 271 
of a pathogenic finding in and of itself or whether this is an epiphenomenon which reflects the overall disease 272 
burden in a manner different from acute illness scores. Microbial DNA certainly has the capacity to be inherently 273 
pathogenic. Unmethylated CpG dinucleoties, such as are found in microbial DNA, are known to be potent TLR9 274 
agonists and binding can result in inflammatory cascades [16,17]. Microbial DNA is also a key component of 275 
biofilms, where it contributes to their structural stability and also plays an active role in the inhibition of antibiotics 276 
[18]. This may be particularly relevant in an ICU population where biofilms are frequently present on indwelling 277 
medical devices such as endotracheal tubes and venous catheters and where the presence of a biofilm may be a 278 
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factor in the failure to grow an organism using culture techniques.  Alternatively, the presence of microbial DNA 279 
may indicate the presence of active infection which a poorly sensitive test such as blood culture fails to identify. We 280 
have previously reported that PCR/ESI-MS can readily identify fastidious and difficult to culture organisms [12]. It 281 
is also plausible that a positive PCR/ESI-MS result is merely an epiphenomenon of more severe disease and perhaps 282 
related to leakage of microbial contents from a porous gastrointestinal tract.  283 
We did not demonstrate an association between any individual microbial species and subsequent outcome but this 284 
study is likely underpowered to detect any such an association. Furthermore, as the current PCR/ESI-MS technology 285 
detects only KPC, vanA, vanB and mecA as antibiotic resistance genes and these were detected at a very low 286 
frequency in our patients no definitive statement can be made regarding patient outcome in the presence of DNA 287 
from highly resistant organisms. Although the presence of multi-drug resistant organisms is likely to have a 288 
significant impact on determining patient outcome the relatively low incidence of culture positive sepsis in our 289 
patients limited further analysis of this association.  290 
This analysis is specific to one particular methodology of microbial D A detection – PCR/ESI-MS. A numerous 291 
other technologies are available to detect microbial DNA. Two previous studies using other techniques did not 292 
suggest that the detection of microbial DNA was associated with an higher mortality although they did report an 293 
association between microbial DNA and a more severe acute illness [19,20]. This has led many investigators to 294 
question the relevance of microbial DNA in the bloodstream of a patient where viable microbes could not be 295 
cultured [21]. That our study describes a mortality difference may be partly explained by the diagnostic spectrum of 296 
the PCR/ESI-MS technology that is able to identify in excess of 800 microbes in a culture independent method in 297 
comparison to other PCR technology that usually limits detection to approximately 25 common pathogens and 298 
frequently requires enrichment via standard culture methodologies [19,22,23].  299 
There are some limitations to the analyses presented here. During this study the PCR/ESI-MS result was not 300 
available to the treating clinicians and therefore could not influence treatment whereas the blood culture results were 301 
obtained as part of routine clinical care and results were available as normal. It is therefore plausible that patients 302 
with negative blood cultures and positive PCR/ESI-MS results may have had their antibiotic treatment ceased 303 
inappropriately early thereby affecting subsequent outcome.  However, we found that the duration of antibiotic 304 
treatment was similar between those patients that had a positive PCR/ESI-MS result regardless of whether their 305 
blood culture result was positive or negative. Indeed, the duration of antibiotic treatment was similar amongst all 306 
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combinations of test results. In addition, given the limited resistance profiling of the current PCR/ESI-MS 307 
technology discussed earlier we were unable to comment on whether patients with a positive PCR/ESI-MS result 308 
received adequate antibiotic treatment during the study period. Finally, although each institute obtained blood 309 
cultures according to local protocols the lack of specific standardisation for this procedure could plausibly affect 310 
microbial yield and thus study results.  311 
If replicated, these results could potentially alter management of the patients in the future. If the presence of 312 
microbial DNA represents a sub optimally treated infected process then specific antibiotic regimes may be suggested 313 
based on this test result. This approach would be greatly facilitated by the expanding the currently available panel of 314 
antibiotic resistance genes detected by PCR/ESI-MS technology. As the field of sepsis immunotherapy and 315 
personalised medicine rapidly expands PCR/ESI-MS may prove to have a role in identifying patients that would 316 
benefit from specific antagonism of TLR9 pathways or even from adjunctive immune stimulation [24-26]. Further 317 
mechanistic studies are required prior to suggesting more specific treatments. 318 
 319 
 320 
 321 
 322 
 323 
 324 
 325 
 326 
 327 
 328 
 329 
 330 
 331 
 332 
 333 
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Conclusions 335 
According to our best knowledge this is the first paper that reports that the presence of microbial DNA in the blood-336 
stream of patients with suspected acute sepsis is associated with greater mortality. It is plausible that PCR/ESI-MS 337 
result may provide additional important information as regards the clinical trajectory of the patient with suspected 338 
sepsis above that garnered from the traditional blood culture results and from an assessment of the severity of 339 
illness. It is plausible that this assay could be used to direct specific adjunctive therapies to a high risk population 340 
with suspected sepsis. 341 
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Table 1. Demographic and clinical features of the study population 424 
 Total cohort BC+ve BC-ve p PCR+ve PCR-ve p 
 (n=439) (n=56) (n=383)  (n=177) (n=262)  
Demographics        
Median age (years, median/IQR) 65(49-75) 64(48-71) 66(50-76) 0.2 66(54-78) 64(46-72) 0.01 
Sex (male) 66% 69% 63% 0.2 64% 66% 0.9 
Major comorbidities at baseline        
Hypertension 47% 54% 46% 0.3 49% 45% 0.5 
Diabetes 24% 27% 23% 0.6 24% 23% 0.8 
Cancer 29% 30% 29% 0.9 34% 26% 0.09 
CKD 18% 23% 17% 0.3 18% 17% 0.8 
Cirrhosis 8% 7% 9% 0.99 10% 8% 0.5 
COPD or asthma 20% 9% 21% 0.03 15% 23% 0.04 
Current smoker 15% 7% 16% 0.1 14% 15% 0.8 
Immunosupressed 14% 20% 13% 0.2 16% 12% 0.2 
Antimicrobial use        
Within 30 days prior to hospitalisation 11% 9% 12% 0.8 10% 12% 0.9 
During hospitalisation but before 
enrolment 
59% 57% 60% 0.8 58% 60% 0.6 
Illness severity on study enrolment        
SOFA score on enrolment (median and 
IQR) 
7 (4-11) 10 (6-12) 7 (4-11) 0.01 8 (5-11) 7 (4-10) 0.005 
qSOFA score on enrolment (median and 
IQR) 
1 (1-2) 1 (1-2) 1 (1-2) 0.2 1 (1-2) 1 (1-2) 0.1 
Vasopressor use on enrolment 55% 68% 53% 0.04 62% 50% 0.02 
Requirement for MV on enrolment 59% 54% 59% 0.5 66% 54% 0.02 
A description of the demographic and clinical features of the patient population on enrolment in the study.  425 
Abbreviations: BC+ve, positive blood culture; BC-ve, negative blood culture; PCR+ve, positive polymerase chain reaction / electrospray 426 
ionization-mass spectrometry; PCR-ve, negative polymerase chain reaction / electrospray ionization-mass spectrometry; Vasopressors were 427 
defined as either noradrenaline or vasopressin. IQR, inter quartile range; CKD, chronic kidney disease; COPD, chronic obstructive airways 428 
disease; SOFA, sequential organ failure assessment score; qSOFA, quick SOFA; IQR, interquartile range; MV, mechanical ventilation.  429 
 430 
 431 
 432 
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Table 2. Post-enrolment patient characteristics 433 
 Total 
cohort 
BC+ve BC-ve p PCR+ve PCR-ve p 
ICU LOS 7(4-14) 7(3-13) 7(4-14) 0.8 8(4-13) 7(4-14) 0.8 
Hospital LOS 23(12-39) 23(10-48) 23(13-38) 0.8 22(12-41) 23(13-37) 0.9 
Days of mechanical ventilation 2(0-8) 1(0-7) 2(0-8) 0.4 3(0-9) 2(0-7) 0.03 
Days alive and free of MV to day 28 26(20-28) 27(21-28) 26(20-28) 0.4 26(19-28) 27(21-28) 0.03 
Days on vasopressors 1(0-4) 2(0-5) 1(0-4) 0.08 2(0-5) 0(0-4) 0.007 
Days alive and free of vasopressors to day 
28 
27(24-28) 26(23-28) 27(24-28) 0.07 26(24-28) 28(24-28) 0.01 
Days on antibiotics 7(4-11) 6(3-13) 7(4-11) 0.2 7(3-13) 7(4-11) 0.9 
Days free of A/B and alive up to day 28 10(0-22) 4(0-22) 12(0-22) 0.3 4(0-21) 17(1-23) 0.003 
A description of the hospital stay and illness characteristics following enrolment in the study.  Days alive and free of (MV/ vasopressors/ 434 
antibiotics) today 28 was calculated by adding the number of days up to and including day 28 that the patient was both free of the intervention 435 
and alive.    436 
Abbreviations: BC+ve, positive blood culture; BC-ve, negative blood culture; PCR+ve, positive polymerase chain reaction / electrospray 437 
ionization-mass spectrometry; PCR-ve, negative polymerase chain reaction / electrospray ionization-mass spectrometry; ICU, intensive care unit; 438 
LOS, length of stay; MV, mechanical ventilation; A/B, antibiotics  439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
 449 
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Table 3. Univariable and multivariable logistic regression analysis of 28-day mortality 451 
Predictor Univariable Multivariable 
p OR (95% CI) p OR (95% CI) 
Age (per year) <0.0001 1.05 (1.03-1.07) <0.0001 1.05 (1.03-1.07) 
SOFA score (per unit) <0.0001 1.15 (1.09-1.22) <0.0001 1.15 (1.08-1.23) 
History of cancer 0.02 1.8 (1.1-2.8) 0.02 1.8 (1.08-3.15) 
Immune suppression 0.04 1.9 (1.1-3.6) 0.14 1.8 (0.8-3.7) 
Positive PCR/ESI-MS 0.001 2.1 (1.4-3.3) 0.04 1.7 (1.01-2.82) 
Positive BC 0.74 1.1 (0.6-2.1)   
Cardiovascular disease 0.5 1.3 (0.7-2.3)   
Respiratory disease 0.7 1.3 (0.67-2.0)   
Diabetes mellitus 0.5 1.2 (0.72-2.0)   
Chronic kidney disease 0.7 1.1 (0.6-2.0)   
Cirrhosis 0.6 1.4 (0.6-2.7)   
History of smoking 0.5 1.3 (0.7-2.7)   
The C statistic for the whole model is 0.77. Abbreviations: OR, odds ratio; CI, confidence interval; SOFA, sequential organ failure assessment 452 
score; PCR/ESI-MS, polymerase chain reaction/electrospray ionization-mass spectrometry; BC, blood culture 453 
 454 
 455 
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 457 
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 459 
 460 
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 462 
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Table 4. Organism specific outcomes 468 
Commonest organisms by  blood culture Mortality % (n) Commonest organism by PCR/ESI-MS Mortality %(n) 
1 Escherichia coli 60% (6/15) 1 Escherichia coli 43% (23/53) 
2 Staphylococcus aureus 11% (1/9) 2 Staphylococcus aureus 40% (8/20) 
3 Klebsiella pneumoniae 75% (3/4) 3 Enterococcus faecium 65% (11/17) 
4 Pseudomonas aeruginosa 50% (2/4) 4 Klebsiella pneumoniae 40% (4/10) 
5 Enterococcus faecium 50% (1/2) 5 Candida albicans 56% (5/9) 
28-day organism specific mortality for five most commonly isolated organisms by blood culture and by PCR/ESI-MS.  469 
 470 
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Figure 1. 28-day mortality. 
 
Amongst those patients that have a negative blood culture result those with a positive PCR/ESI-MS test result 
have a higher mortality. A McNemar’s Test was performed on the non-surviving patients which indicated that 
the total number of positive tests for each method was statistically different (McNemar test statistic = 45, degree 
of freedom  = 1 and p<0.0001).  
BC, blood culture. PCR/ESI-MS, Polymerase chain reaction followed by electrospray ionisation-mass 
spectrometry 
 
